Author Correction: Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion

W. Tang, D. Zhu, F. Wu, J.-F. Xu, J.-P. Yang, Z.-P. Deng, X.-B. Chen, A. Papi, J.-M. Qu

Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

---

• Respiratory Medicine

Eur Rev Med Pharmacol Sci 2023; 27 (11): 5119-5127–DOI: 10.26355/eurrev_202306_32628–PMID: 37318485, published online on June 13, 2023.

After publication, the authors have found some mistakes. This erratum corrects the following:

• In Figure 1, “4 withdrawal” has been corrected into “7 withdrawal” and “95 completed study” has been corrected into “97 corrected study”

• In the “Efficacy” paragraph at page 5123, “1.0 in the placebo group” has been corrected into “-1.0 in the placebo group”.

• The legend of Table V has been corrected as follows: Table V. Published clinical studies of the mucolytic and expectorant efficacy of IV NAC in respiratory diseases.
• In Table V, the data regarding the Treatment groups (duration) by Grassi et al5 have been corrected as follows:

NAC oral 200 mg TID

NAC IM 300 mg BID

NAC IV 500 mg OD (6 days)

• In Table V, the data regarding the Treatment groups (duration) by Henneghien et al8 have been corrected as follows:

NAC oral 200 mg TID

NAC IV 300 mg TID (3-10 days)

NAC IV 500 mg BID (12 days)

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.

Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion

Free PDF Download